Biogen Inc.
General ticker "BIIB" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $22.4B (TTM average)
Biogen Inc. follows the US Stock Market performance with the rate: 47.0%.
Estimated limits based on current volatility of 1.9%: low 191.22$, high 198.58$
Factors to consider:
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 7605 (+0.5%) as of 2024
- US accounted for 1.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Market competition, Strategic risks and growth management, Capital expenditures, Fit for growth
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [142.32$, 204.37$]
- 2026-12-31 to 2027-12-31 estimated range: [157.51$, 222.12$]
Financial Metrics affecting the BIIB estimates:
- Negative: with PPE of 11.4 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 16.30
- Positive: 6.59 < Operating cash flow per share per price, % of 8.59
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 4.21
- Positive: Industry inventory ratio change (median), % of 0.28 <= 0.28
- Positive: -14.17 < Investing cash flow per share per price, % of -5.34
- Positive: Inventory ratio change, % of -1.77 <= -0.75
Short-term BIIB quotes
Relationship graph
Long-term BIIB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $9,520.10MM | $9,675.90MM | $9,551.40MM |
| Operating Expenses | $7,422.80MM | $7,185.60MM | $7,994.90MM |
| Operating Income | $2,097.30MM | $2,490.30MM | $1,556.50MM |
| Non-Operating Income | $-800.50MM | $-584.30MM | $0.00MM |
| Interest Expense | $246.90MM | $250.30MM | $0.00MM |
| R&D Expense | $2,702.60MM | $2,488.50MM | $1,778.60MM |
| Income(Loss) | $1,296.80MM | $1,906.00MM | $1,556.50MM |
| Taxes | $135.30MM | $273.80MM | $263.60MM |
| Net Income(Loss)* | $1,161.10MM | $1,632.20MM | $1,292.90MM |
| Stockholders Equity | $14,799.40MM | $16,716.00MM | $18,256.80MM |
| Inventory | $2,527.40MM | $2,460.50MM | $2,168.10MM |
| Assets | $26,844.80MM | $28,049.30MM | $29,439.50MM |
| Operating Cash Flow | $1,547.20MM | $2,875.50MM | $2,204.60MM |
| Capital expenditure | $311.40MM | $359.80MM | $153.80MM |
| Investing Cash Flow | $-4,088.70MM | $-799.20MM | $-1,371.10MM |
| Financing Cash Flow | $137.00MM | $-683.50MM | $-301.90MM |
| Earnings Per Share** | $8.02 | $11.20 | $8.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.